NNVC ▼ -2.1% - NanoViricides, Inc. $NNVC - Clinical Trial of the Oral Drug NV-387 to Treat Ebola Has Started Enrollment and Dosing of Patients Last Week (on or about September 23rd), Says NanoViricides 28-SEP-2026 08:45 AM ET